This federal Project Grant award from the National Eye Institute (NEI) under CFDA Program 93.867 (Vision Research) supports the development of a refillable, micromachined lens capsule-based drug delivery device for extended localized treatment of ocular inflammation associated with noninfectious uveitis. The $257,785 award, effective from April 1, 2025 to March 31, 2029, aims to characterize and control the release of the biologic drug adalimumab and an immune-modulating peptide from this engineered intraocular drug delivery system, both in vitro and in vivo using a rabbit model. The goal is to provide new therapies for ocular inflammation without the side effects of current steroid-based treatments. The project is being conducted by The Leland Stanford Junior University, a leading private research institution.
Generated 3/25/25, 2:53 AM